News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sanofi (France) (SAN.PA) Relying On Partnership With Regeneron Pharmaceuticals, Inc. (REGN) To Save Its R&D Reputation


2/10/2014 8:43:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

French drugmaker Sanofi has been one of the weaker players in the industry in terms of new product launches in recent years, but that is set to change, says chief executive Chris Viehbacher. Discussing the company's R&D heritage on Sanofi's fourth-quarter results call, Viehbacher conceded that Sanofi "hasn't brought a lot of new products to market in the last 10 years", with drugs launched since 2009 contributing less than €1bn to its turnover last year. Now, Sanofi has it has "one of the better pipelines in the industry" said Viehbacher, with nine late-stage projects that may potentially be filed over the next 4 years in several disease areas, including diabetes, vaccines, cardiovascular and immunology.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES